Statin discontinuation: An underestimated risk?

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3059-3062

  Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^b   Mikhailidis, Dimitri P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Adherence; Coronary heart disease; Myocardial infarction; Vascular risk

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ACUTE HEART INFARCTION; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; TREATMENT WITHDRAWAL;

CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; STATISTICS AS TOPIC; TREATMENT OUTCOME; VASCULAR DISEASES; WITHHOLDING TREATMENT;

EID: 65649111584     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802469102     Document Type: Review

References (43)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
2. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
3. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-2414
4. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-1847 (Pubitemid 44455166)
5. Heeschen C, Hamm CW, Laufs U, et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-1452
6. Colivicchi F, Bassi A, Santini M, et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007;38:2652-2657 (Pubitemid 47493999)
7. Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008;66:110-116 (Pubitemid 351822170)
8. Lesaffre E, Kocmanová D, Lemos PA, et al. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003;25:2431-2447 (Pubitemid 37267250)
9. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-467 (Pubitemid 34787477)
10. Kamal-Bahl SJ, Burke T, Watson D, et al. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-534 (Pubitemid 46215558)
11. Liberopoulos EN, Florentin M, Mikhailidis DP, et al. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf, in press.
12. Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; Jul 29 [Epub ahead of print]
13. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-186 (Pubitemid 46089734)
14. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-233 (Pubitemid 34913500)
15. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028-1036
16. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 2005;16:65-71
17. Fonarow GC, Wright RS, Spencer FA, et al.; National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005;96:611-616
18. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003;107:27
19. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69:904-910 (Pubitemid 47329591)
20. McGowan MP; Treating to New Target (TNT) Study GroupThere is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004;110:2333-2335 (Pubitemid 39407335)
21. Collard CD, Body SC, Sherman SK, et al.; Multicenter Study of Perioperative Ischemia (MCSPI) Research Group, Inc.; Ischemia Research and Education Foundation (IREF) InvestigatorsPreoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006;132:392-400
22. Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-320 (Pubitemid 47041993)
23. Fleisher LA, Beckman JA, Brown KA, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;116:e418-99
24. Paraskevas KI, Liapis CD, Hamilton G, et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg 2006;32:286-293 (Pubitemid 44207905)
25. Paraskevas KI, Hamilton G, Mikhailidis DP. Statins: an essential component in the management of carotid artery disease. J Vasc Surg 2007;46:373-386
26. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59:564-573 (Pubitemid 40632247)
27. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-1724
28. Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708 (Pubitemid 46753568)
29. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540-556 (Pubitemid 37122048)
30. Lee KT, Lai WT, Chu CS, et al. Effect of withdrawal of statin on C-reactive protein. Cardiology 2004;102:166-170 (Pubitemid 39370270)
31. Li JJ, Li YS, Chu JM, et al. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia. Clin Chim Acta 2006;366:269-273 (Pubitemid 43330994)
32. Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007;11:1143-1160 (Pubitemid 47532862)
33. Westphal S, Abletshauser C, Luley C. Fluvastatin treatment and withdrawal: effects on endothelial function. Angiology 2008; Apr 14 [Epub ahead of print]
34. Taneva E, Borucki K, Wiens L, et al. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal. Am J Cardiol 2006;97:1002-1006
35. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003;9:2425-2443 (Pubitemid 37236363)
36. Lai WT, Lee KT, Chu CS, et al. Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation. Int J Cardiol 2005;98:459-464 (Pubitemid 40247937)
37. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126 (Pubitemid 29054847)
38. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 2006;26:1288-1296 (Pubitemid 44306889)
39. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-1870 (Pubitemid 38509499)
40. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15 (Pubitemid 44406838)
41. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CCT) Collaborators. Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
42. Spencer FA, Allegrone J, Goldberg RJ, et al.; GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140:857-866
43. Athyros VG, Tziomalos K, Mikhailidis DP, et al. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opin Pharmacother 2007;8:2267-2277 (Pubitemid 350001589)